Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.46 |
| ▸ | CTSK | P43235 | 5/20 | 0.42 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.41 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.41 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.41 |
| ▸ | CTSL | P07711 | 1/20 | 0.41 |
| ▸ | CTSB | P07858 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28948946 | 1.00 | LTA4H (0.46) | LTA4HCTSKSLC1A3SLC1A2SLC1A1 | |
| SCHEMBL19817250 | 1.00 | LTA4H (0.46) | LTA4HCTSKSLC1A3SLC1A2SLC1A1 | |
| SCHEMBL5326239 | 1.00 | LTA4H (0.46) | LTA4HCTSKSLC1A3SLC1A2SLC1A1 | |
| SCHEMBL14947101 | 1.00 | LTA4H (0.46) | LTA4HCTSKSLC1A3SLC1A2SLC1A1 | |
| SCHEMBL17276053 | 0.98 | LTA4H (0.44) | LTA4HCTSKSLC1A3SLC1A2SLC1A1 | |
| SCHEMBL18050391 | 0.98 | LTA4H (0.44) | LTA4HCTSKSLC1A3SLC1A2SLC1A1 | |
| SCHEMBL13285738 | 0.98 | LTA4H (0.44) | LTA4HCTSKSLC1A3SLC1A2SLC1A1 | |
| Hydrochloric Acid SCHEMBL16054796 | 0.96 | LTA4H (0.43) | LTA4HCTSKSLC1A3SLC1A2SLC1A1 | |
| SCHEMBL10138774 | 0.93 | LTA4H (0.41) | LTA4HSLC1A3SLC1A2SLC1A1 | |
| SCHEMBL19815021 | 0.93 | LTA4H (0.41) | LTA4HSLC1A3SLC1A2SLC1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12590078-B2 | — | — | 2026-03-31 | — | — | US | disclosed |
| US-12466805-B2 | Pharmaceutical compounds | ALMAC DISCOVERY LIMITED (GB) | 2025-11-11 | — | — | US | disclosed |
| US-11807646-B2 | 4-hydroxypiperidine derivatives and their use as inhibitors of ubiquitin specific protease 19 (USP19) | ALMAC DISCOVERY LIMITED (GB) | 2023-11-07 | — | — | US | disclosed |
| US-11807646-B2 | 4-hydroxypiperidine derivatives and their use as inhibitors of ubiquitin specific protease 19 (USP19) | ALMAC DISCOVERY LIMITED (GB) | 2023-11-07 | — | — | US | disclosed |
| US-11807646-B2 | 4-hydroxypiperidine derivatives and their use as inhibitors of ubiquitin specific protease 19 (USP19) | ALMAC DISCOVERY LIMITED (GB) | 2023-11-07 | — | — | US | disclosed |
| US-20230133600-A1 | PHARMACEUTICAL USE OF KETOAMIDE-BASED COMPOUND | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2023-05-04 | — | — | US | disclosed |
| EP-3746432-B1 | 4-HYDROXYPIPERIDINE DERIVATIVES AND THEIR USE AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 19 (USP19) | ALMAC DISCOVERY LTD (GB) | 2022-12-14 | — | — | EP | disclosed |
| WO-2022224035-A2 | ANTI-GM1 ANTIBODY BINDING COMPOUNDS | POLYNEURON PHARMACEUTICALS AG (CH) | 2022-10-27 | — | — | WO | disclosed |
| CN-115190795-A | PEGylated uricase formulations and dosages | 西莱克塔生物科技公司 | 2022-10-14 | — | — | CN | disclosed |
| CN-109790146-B | Pharmaceutical compounds | 阿尔麦克探索有限公司 | 2022-08-23 | — | — | CN | disclosed |
| WO-2019150119-A1 | 4-HYDROXYPIPERIDINE DERIVATIVES AND THEIR USE AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 19 (USP19) | ALMAC DISCOVERY LIMITED (GB) | 2019-08-08 | — | — | WO | disclosed |
| WO-2019150119-A1 | 4-HYDROXYPIPERIDINE DERIVATIVES AND THEIR USE AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 19 (USP19) | ALMAC DISCOVERY LIMITED (GB) | 2019-08-08 | — | — | WO | disclosed |
| US-20190233394-A1 | PHARMACEUTICAL COMPOUNDS | ALMAC DISCOVERY LIMITED (GB) | 2019-08-01 | — | — | US | disclosed |
| US-20190233394-A1 | PHARMACEUTICAL COMPOUNDS | ALMAC DISCOVERY LIMITED (GB) | 2019-08-01 | — | — | US | disclosed |
| EP-3490982-A1 | PHARMACEUTICAL COMPOUNDS | Almac Discovery Limited (GB) | 2019-06-05 | — | — | EP | disclosed |
| WO-2018020242-A1 | PHARMACEUTICAL COMPOUNDS | ALMAC DISCOVERY LIMITED (GB) | 2018-02-01 | — | — | WO | disclosed |
| EP-0837845-B1 | HERPES RIBONUCLEOTIDE REDUCTASE INHIBITORS | BOEHRINGER INGELHEIM CA LTD (CA) | 2001-11-28 | — | — | EP | disclosed |
| EP-0837845-A1 | HERPES RIBONUCLEOTIDE REDUCTASE INHIBITORS | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 1998-04-29 | — | — | EP | disclosed |
| US-5672586-A | Herpes ribonucleotide reductase inhibitors | BIO-MEGA/BOEHRINGER INGELHEIM RESEARCH, INC. (CA) | 1997-09-30 | — | — | US | disclosed |
| WO-1997000855-A1 | HERPES RIBONUCLEOTIDE REDUCTASE INHIBITORS | BOEHRINGER INGELHEIM (CANADA) LTD./BOEHRINGER INGELHEIM (CANADA) LTÉE. (CA) | 1997-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230133600-A1 | PHARMACEUTICAL USE OF KETOAMIDE-BASED COMPOUND | CTSL, CTSV, CTSS | LTA4H 82/4885CTSK 13/4885SLC1A3 2031/4885 |
| US-12466805-B2 | Pharmaceutical compounds | USP19, USP18, UBE2I | LTA4H 514/4885CTSK 249/4885SLC1A3 4309/4885 |
| US-20190233394-A1 | PHARMACEUTICAL COMPOUNDS | USP19, USP18, UBE2I | LTA4H 514/4885CTSK 249/4885SLC1A3 4309/4885 |
| US-12590078-B2 | — | ADRM1, USP19, USP1 | LTA4H 4020/4885CTSK 2624/4885SLC1A3 2740/4885 |
| US-11807646-B2 | 4-hydroxypiperidine derivatives and their use as inhibitors of ubiquitin specific protease 19 (USP19) | USP19, USP16, USP18 | LTA4H 2300/4885CTSK 1507/4885SLC1A3 4736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.